Resveratrol (1) is a naturally occurring phytoalexin that affects a variety of human disease models, including cardio- and neuroprotection, immune regulation, and cancer chemoprevention. One of the possible mechanisms by which resveratrol affects these disease states is by affecting the cellular signaling network involving protein kinase C (PKC). PKC is the family of serine/threonine kinases, whose activity is inhibited by resveratrol. To develop PKC isotype selective molecules on the resveratrol scaffold, several analogs (2–5) of resveratrol with a long aliphatic chain varying with number of unsaturated doubled bonds have been synthesized, their cytotoxic effects on CHO-K1 cells are measured and their effects on the membrane translocation properties of PKCα and PKCε have been determined. The analogs showed less cytotoxic effects on CHO-K1 cells. Analog 4 with three unsaturated double bonds in its aliphatic chain activated PKCα, but not PKCε. Analog 4 also activated ERK1/2, the downstream proteins in the PKC signaling pathway. Resveratrol analogs 2–5, however, did not show any inhibition of the phorbol ester-induced membrane translocation for either PKCα or PKCε. Molecular docking of 4 into the activator binding site of PKCα revealed that the resveratrol moiety formed hydrogen bonds with the activator binding residues and the aliphatic chain capped the activator binding loops making its surface hydrophobic to facilitate its interaction with the plasma membrane. The present study shows that subtle changes in the resveratrol structure can have profound impact on the translocation properties of PKCs. Therefore, resveratrol scaffold can be used to develop PKC selective modulators for regulating associated disease states.
Citation: Pany S, Majhi A, Das J (2012) PKC Activation by Resveratrol Derivatives with Unsaturated Aliphatic Chain. PLoS ONE 7(12): e52888. https://doi.org/10.1371/journal.pone.0052888
Editor: Jon CD. Houtman, University of Iowa, United States of America
Received: October 25, 2012; Accepted: November 22, 2012; Published: December 21, 2012
Copyright: © 2012 Pany et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Resveratrol (1, Figure 1) is a naturally occurring phytoalexin found in grapes, red wine, peanuts, olive oil, cranberries, and other food , . Numerous studies highlighted the effects of resveratrol in a variety of human disease models, including cardio- and neuroprotection, immune regulation, and cancer chemoprevention –. Some of the recent studies evaluated its promising biological properties, ,  including antioxidant activity,  antiestrogenic activity  inhibition of cyclooxygenase  and inhibition of platelet aggregation . Resveratrol showed chemopreventive activities against human degenerative diseases such as atherosclerosis  and cancer . Resveratrol showed cancer chemopreventive activity in assays representing anti-initiation, anti-promotion and antiprogression activity, inhibiting the development of preneoplastic lesions and tumorigenesis . Further evidence showed that it inhibits cell growth and induces apoptosis in various human cancer cell lines –. In particular, a number of studies reported the chemopreventive activity of resveratrol against prostate cancer –. Resveratrol is also currently in clinical phase II trials as an anti-cancer drug for treatment of human colon cancer , .
Resveratrol displays its biological response by acting on multiple targets. The activity of resveratrol has been linked to cell-surface receptors, membrane signaling pathways, intracellular signal-transduction machinery, nuclear receptors, gene transcription, and metabolic pathways , . Protein kinase C (PKC) is one of the many targets of resveratrol.
PKC – belongs to the family of serine/threonine kinases involved in the regulation of various aspects of cell functions, including cell growth, differentiation, metabolism, and apoptosis . PKC's role has been implicated in the pathology of several diseases such as cancer, diabetes, stroke, heart failure, and Alzheimer's disease –. PKC has been a subject of intensive research and drug development in the area of cancer .
The PKC family has been divided into three main groups: conventional isoforms (α, βI, βII and γ) that require Ca2+ and diacylglycerol (DAG) for activation; novel isoforms (δ, ε, η, θ and µ) that require only DAG and atypical isoforms (ζ, ι and λ) that require neither Ca2+ nor DAG . The conventional and novel PKCs have four domains, termed C1 through C4, that play distinct roles in kinases' function. C1 and C2 are regulatory domains, C3 is the ATP binding domain, and C4 is the catalytic domain. DAG contains two long chains, acts as a second messenger  by binding to the C1 domain and inducing the translocation of PKCs to discrete subcellular compartments. Phorbol esters, which are isolated from plants, activate PKCs several fold higher than DAG by binding to the C1 domain. In the conventional and novel PKC isoenzymes, the DAG-sensitive C1 domain is duplicated into a tandem C1 domain consisting of C1A and C1B subdomains. The C1 domains have become an attractive target in designing the PKC based drugs. Recently, it has been found that alcohol and anesthetics also bind to the PKC C1 domains –.
The biological effects of resveratrol on PKCs have been studied both in the cellular system and in in vitro purified proteins. Resveratrol regulates cellular PKCα and PKCδ to inhibit growth and induce apoptosis in gastric cancer cells . It also inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells  and antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKCα inhibition . Resveratrol also preferentially inhibits PKC-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism .
The mechanism of the effects of resveratrol on the activities of purified recombinant PKC isozymes induced by association with model lipid vesicle membranes was investigated using an in vitro assay system in which the cofactor and activator-concentration dependencies for activation were systematically varied . It was found that resveratrol inhibited membrane-associated PKCα activity within a concentration range relevant to the cellular effects of the stilbene , , – and it was proposed that resveratrol binds to the C1 domain of PKCα . In a previous study, we measured the effect of several resveratrol derivatives on PKCα activity in HEK293 cells .
In the present study, we describe the synthesis of several resveratrol derivatives having unsaturated aliphatic chain and their effects on the translocation properties of PKCα and PKCε in the presence and absence of a phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Our results show that chemical modification of one of the hydroxyl groups of resveratrol with aliphatic carbon chain reduced its cytotoxicity on CHO-K1 cells. Modification with a linolenyl chain completely abolished resveratrol's inhibitory effects on PKC. Instead, the molecule activated PKCα and the downstream protein ERK1/2 in the PKC signaling pathway.
Absorption and emission spectra of resveratrol (1) and its derivatives (2–5)
The absorption and emission maxima of resveratrol (1) and its derivatives (2–5) in various organic solvents are listed in Table 1. Figure 2A shows the representative absorption spectra of 2 in different solvent. Resveratrol (1) showed broad absorption maxima in the range of 304–318 nm with two humps at around 306 nm and 319 nm. This band did not show any significant wavelength shift when the solvent was switched from polar ethanol to nonpolar hexane. For the resveratrol derivatives 2–4, absorbance of the 319 nm band was slightly higher than the 306 nm band in ethanol and acetonitrile and the absorbance of the 306 nm band was higher than the 319 nm band in hexane and water. For compound 5, the 306 nm band was higher than the 319 nm bands in ethanol, acetonitrile and hexane, whereas in water it showed a 275 nm band.
A), Normalized absorption and B) normalized florescence emission spectra of 2 in a) water, b) ethanol, c) acetonitrile and d) hexane.
The emission maximum of resveratrol is in the range of 373–379 nm in organic solvents, whereas it is red shifted to 392 nm in water. Similar to the emission characteristics of resveratrol, the derivatives 1–5 also showed highest emission maxima values in water and the lowest emission maximum values in hexane (Figure 2B). There was no significant difference in the emission maxima values of 2, 3 and 4, in which the number of unsaturated double bonds were different.
Overall, the chemical modification of resveratrol in 2–5 did not show any significant changes in the absorption and emission characteristics of resveratrol.
Effect of 1–5 on cell viability
Resveratrol is known to exert toxic effects on different cell lines . Results shown in Figure 3 indicated that resveratrol produced a marked, concentration dependent reduction in number of viable CHO-K1 cells. For resveratrol, ∼30% cell viability was observed at 25 µM and ∼ 15% cell viability was observed at 100 µM as compared to the untreated control cells. In contrast, for compounds 2–5 cell viability was much higher as compared to resveratrol. Additionally, no significant differences were observed among 2–5, which contained different number of unsaturated double bonds. In conclusion, modification of resveratrol with unsaturated hydrocarbon chain significantly reduced the cytotoxicity of resveratrol.
The graph shows the percentage of viable cell after treatment with 1–5 at three different concentrations for 48 h. The cell viability was measured by MTT assay. Mean and standard deviation (SD) were obtained from three experiments done in triplicate.
After evaluating the cytotoxic property of resveratrol and its derivatives, we studied the effect of these derivatives on expression, activation and inhibition of PKCα and PKCε.
Effect of 1–5 on PKCα and PKCε expression
Effect of 1–5 on the expression of PKCα and PKCε was examined by immunoblot methods using the whole cell lysate of CHO-K1 cells treated with the compounds (10 µM) for 24 h. Results indicated that PKCα expression was significantly reduced (∼60%) when the cells were treated with 1 as compared to the untreated cells (Figure 4). About 30% decrease in PKCα expression was observed for 2. In contrast, 4 showed increase in expression, but 3 and 5 did not show any effect on PKCα expression. Moreover, none of these compounds showed any effect on the expression of PKCε. To summarize, no particular trend is observed on their effects on PKCα expression, however compound 4 with three unsaturated double bonds increased the expression of PKCα, but not of PKCε in CHO-K1 cells.
Upper panels, Western blot analysis of whole cell lysate of CHO-K1 cells after treatment with 1–5 (10 µM) for 24 h. Lower panel, bar graph of densitometry analysis of PKC expression (Mean ± SE, *P<0.05, n = 3). β actin was used as a reference for uniform loading. Control refers to the sample with no addition of compounds.
Effect of 1–5 on membrane translocation of PKCα and PKCε
Effects of 1–5 on the translocation properties of PKCα and PKCε were measured at two different incubation times, 1 h and 24 h. Incubation of resveratrol (1) at 25–100 µM for 1 h with either PKCα or PKCε did not show any PKC membrane translocation. Under the similar condition however, 100 nM TPA caused almost complete membrane translocation of both PKCα and PKCε (Figure 5). For compounds 2, 3, 4 and 5 also, no translocation of either PKCα or PKCε was observed (Figures 6 and 7).
Upper panels, Western blot analysis of the cytosolic (C) and the membrane (M) fractions of (A) PKCα and (B) PKCε after the cells were treated with varying concentration 1 for 1 h. Lower panel, bar graph of densitometry analysis of the upper panel immunoblots (Mean± SE, n = 3). Control refers to the sample with no addition of compounds.
Upper panels, Western blot analysis of the cytosolic (C) and the membrane (M) fractions of (A) PKCα and (B) PKCε after the cells were treated with varying concentration of 4 for 1 h. Lower panel, bar graph depicts the densitometry analysis of the upper panel immunoblots (Mean± SE, n = 3). Control refers to the sample with no addition of compounds.
Upper panels, Western blot analysis of the cytosolic (C) and the membrane (M) fractions of (A) PKCα and (B) PKCε after the cells were treated with 100 µM of 2, 3 or 5 for 1 h. Lower panel, bar graph of densitometry analysis of the upper panel immunoblots (Mean± SE, n = 3). Control refers to the sample with no addition of compounds.
Next, we examined the effects of 1–5 on membrane translocation of PKCα and PKCε with an incubation time of 24 h. Figure 8 shows the distribution of PKCα in cytosol and membrane after cells were treated with varying concentration of 1 and 4. Results indicated that cytosolic PKCα level decreased with increasing concentration of 1, and there was no visible effect on the membrane fraction. In contrast, 4 increased the PKCα level in membrane and its level in cytoplasm remained unchanged. These observations are correlated well with our earlier observation that compound 1 decreased the expression of PKCα and compound 4 increased it. For compound 4, membrane PKCα level considerably increased at the concentration range of 5–10 µM and at concentration higher than 10 µM, this increment was rather small. Therefore, the concentration 10 µM was chosen to study the membrane translocation properties of all the compounds. Figure 9 clearly indicated that compound 4 was able to increase the amount of PKCα in the membrane. However, when cells were treated with 10 µM of 2, 3 or 5 for 24 h, no significant effect on the cytosolic and membrane fraction of PKCα was observed (Fig. 9). Additionally, cells treated with 10 µM of 1–5 also did not show any effect on PKCε. Overall, among all the resveratrol derivatives tested on PKCα and PKCε, 4 is the only compound that increased the amount of PKCα in the membrane at 24 h incubation.
Western blot analysis of the cytosolic (C) and the membrane (M) fractions of PKCα after the cells were treated with varying concentration of 1 and 4 for 24 h. Control refers to the sample with no addition of compounds.
Upper panels, Western blot analysis of the cytosolic (C) and the membrane (M) fractions of (A) PKCα and (B) PKCε after the cells were treated with 10 µM of 2, 3, 4 or 5 for 24 h. Lower panel, bar graph of densitometry analysis of the upper panel immunoblots (Mean± SE, n = 3). Control refers to the sample with no addition of compounds.
To confirm whether the increase of PKCα in the membrane fraction was due to PKCα translocation from cytosol to membrane, we examined the effect of 4 on the activation ERK, the downstream signaling cascade molecule activated by membrane-translocated and activated PKCα.
Effect of 3 and 4 on ERK1/2 phosphorylation
To confirm that the membrane translocation, and the activation of PKCα by 4, is propagated along the signal transduction pathway, the effect of 4 on the activation of the downstream ERK1/2 was undertaken. Activation of ERK1/2 was determined by the extent of its phosphorylation in response to 4. Compound 4 phosphorylated ERK1/2, whereas 3 did not do so (Figure 10). For TPA, as expected, higher extent of phosphorylation was observed in 1 h. The conclusion is that activation of PKCα by 4 is transduced along the signal transduction pathway.
Effect of oleic acid, linoleic acid and linolenic acid on the membrane translocation of PKCα and PKCε
To determine if the unsaturated hydrocarbon chains of 2–4 play any role in the membrane translocation properties of PKCα and PKCε, we examined the effect of oleic acid, linoleic acid and linolenic acid on the membrane translocation of PKCα and PKCε. When CHO-K1 cells were treated separately with 10 µM of oleic acid, linoleic acid and linolenic acid for 24 h, no particular trend was observed in the membrane translocation for these three fatty acids. Oleic acid and linolenic acid both showed about 75% membrane translocation of PKCα from cytosol to membrane (Figure 11). However no effect on PKCα was observed for linoleic acid at this concentration. Furthermore, none of the compounds showed any effect on membrane translocation of PKCε. In conclusion, oleic acid and linolenic acid, which contain one and three unsaturated double bonds respectively, caused the membrane translocation of PKCα.
Upper panels, Western blot analysis of the cytosolic (C) and the membrane (M) fraction of (A) PKCα and (B) PKCε after the cells were treated with 10 µM of oleic acid, linoleic acid or linolenic acid for 24 h. Lower panel, bar graph of densitometry analysis of upper panel immunoblots (Mean± SE, n = 3). Control refers to the sample with no addition of compounds.
A previous study on the effect of fatty acids on PKC translocation in CHO-K1 revealed that oleic acid and linolenic acid translocated a conventional PKC, PKCγ to the membrane, whereas linoleic acid translocated it to the perinuclear membrane. These three fatty acids however did not show significant effect on PKCε .
Effects of 1–5 on TPA-induced membrane translocation of PKCα and PKCε
Studies with both purified and cellular PKCs indicated that resveratrol is a PKC inhibitor and this inhibitory property is isoform specific , . To investigate if chemical modification of resveratrol could affect the inhibitory properties, we examined the effect of 1–5 on the TPA-induced membrane translocation of PKCα and PKCε. When CHO-K1 cells were co-treated with 1–5 (100 µM) and TPA (100 nM) for 1 h, there was ∼45% and ∼20% reductions in the TPA-induced membrane translocation of PKCα and PKCε, respectively (Fig. 12). In contrast, under similar experimental condition, 2–5 did not show any effect on TPA-induced translocation of PKCα and PKCε, as majority of PKC was localized in the membrane, similar to when the cells were treated with TPA alone (Fig. 13). This means that chemical modification of resveratrol with long chains resulted in the complete loss of the inhibitory properties of resveratrol towards both PKCα and PKCε.
Upper panels, Western blot analysis of the cytosolic (C) and the membrane (M) fraction of (A) PKCα and (B) PKCε. Lower panel, bar graph of densitometry analysis of upper panel immunoblots (Mean ± SE, *P<0.05, n = 3). Cells were treated with 100 µM of 1 in the presence and absence of 100 nM TPA for 1 h. Control refers to the sample with no addition of compounds.
Upper panels, Western blot analysis of the cytosolic (C) and membrane (M) fraction of (A) PKCα and (B) PKCε. Lower panel, bar graph of densitometry analysis of upper panel immunoblots (Mean ± SE, n = 3). Cells were treated with 100 µM of 2–5 and 100 nM of TPA for 1 h. Control refers to the sample with no addition of compounds.
The present study represents our ongoing effort of developing isoform selective PKC regulator using simpler chemical scaffolds. In a previous study  we demonstrated that resveratrol moiety, that possesses the hydroxyl pharmacophore of the PKC activator phorbol esters, modulated PKCα activity. In the present study, a series of long chain derivatives of resveratrol with varying degree of unsaturation in the aliphatic chain have been synthesized and their abilities to activate and inhibit PKCα and PKCε have been tested. PKCα and PKCε belong to the conventional and novel type respectively. Unlike our previous study in which the PKCα was overexpressed in HEK293 cells,  in the present study we used CHO-K1 cells where both PKCα and PKCε are endogenously expressed. The rationale for studying the unsaturated long chains is that both phorbol ester and diacylglycerol contain long aliphatic chain with the latter having unsaturation in the chain. An earlier report showed that addition of a long aliphatic chain to the indolactam moiety enhanced PKC activity .
We have thoroughly investigated the activity of PKCα and PKCε by measuring their translocation to the plasma membrane in response to the synthetic derivatives. We observed increase in PKCα in the membrane fraction while the amount in the cytosolic fraction remained similar to the control (panel A of figure 9). The increase in membrane PKCα could be due the increased protein synthesis and concomitant membrane translocation, the extent of which was not quantitatively measured in the present study. However, observed activation of ERK1/2 by 4 strongly suggested that 4 caused membrane translocation of PKCα thereby activating ERK1/2. The major finding of our study is that the modification of the resveratrol moiety reduced cytotoxicity significantly, and compound 4 with three unsaturated double bonds in its aliphatic chain (18∶3), activated PKCα. This property of 4 is quite different from resveratrol which did not activate but inhibited the stimulated activity of PKCα. All the molecules were inert towards PKCε both in the activation and inhibition processes. For resveratrol, we detected 20% inhibition for PKCε and 45% inhibition for PKCα. While our data is consistent with the inhibition data reported earlier for PKCα in PC-3 cells, our PKCε inhibition data is not in agreement with earlier study in PC-3 cell in which the authors reported no inhibition of PKCε. Contrasting results were however reported with purified protein. While Stewart et al  reported that resveratrol inhibited both PKCα and PKCε, Slater et al  reported inhibition of only PKCα, not the PKCε. These discrepancies reflect the differences in the machinery present in different cell lines and variety of lipid mixture and cofactor used in the vitro assay systems.
The resveratrol derivatives were synthesized by combining two moieties, the resveratrol moiety and the fatty acyl chain. While previous studies showed that resveratrol did not activate, but inhibited the phorbol ester induced activation, among all the compounds tested in this study only compound 4 showed activation of PKCα. To find out why compound 4 activated PKCα while the parent resveratrol inhibited PKCα, we did control experiments with the fatty acid component of the structures, the oleic acid, linoleic acid and linolenic acid. Several studies were reported on the effects of fatty acids on PKC activities, showing both activation , – and inhibition,  extent of which depended on the cell type, number and position of the double bonds, state of the protein-whether purified or in cells etc. Our study is closely resembled with the study reported in the CHO-K1 cell line by Shirai et al . In this study both oleic acid and linolenic acid translocated a conventional PKC, PKCγ to the membrane but showed little effect on the novel PKCε. Linoleic acid, on the other hand, translocated PKCγ to the perinuclear region. This is more or less consistent with our results in that PKCε is insensitive towards these fatty acids and our results for PKCα are similar to PKCγ both of which belong to the conventional class of PKC. It is possible that we could not detect the effect of linoleic acid because we measured the translocation of the protein to the membrane, not to the perinuclear region. However, the striking feature of these derivatives is that although both oleic acid and linolenic acid translocated PKCα to the membrane, their fusion with the resveratrol moiety generated different response in that only 4, not 2 translocated PKCα to the membrane. Our results clearly indicated that small changes in the chemical structure could lead to profound effect on the activation and translocation properties of PKCs. That the presence of different degree of unsaturation in the fatty acyl chain alters the properties of membrane, ,  our results also imply that subtle ligand-protein-membrane interactions could dictate the activation mechanism of PKCs.
The observation that resveratrol (1) inhibited TPA-induced PKC activation and competed with phorbol ester but not with the calcium, led Slater et al  propose that resveratrol binds at the phorbol ester binding site of PKCα. Our previous binding and modeling studies  on resveratrol derivatives also supported this prediction. However, addition of an aliphatic chain with unsaturation may alter its activity and protein binding mode. For example, chemical modification of the ultra-potent PKC activator phorbol esters turned them inhibitors of PKCα –. The ability of 4 in the activation of PKCα suggests that 4 could bind to its C1 domain. The energy minimized structure of 4 shown in Fig. 14A, revealed that the aliphatic chain formed a conformation that looked like a hook through which the molecule could anchor with the membrane. When the molecule was docked into the phorbol ester binding site of αC1B, the resveratrol moiety formed hydrogen bonds (the backbone NH of Gly-124 formed two hydrogen bonds with two oxygen atoms of the ester groups both at 2.86 Å, not shown) with the protein residues and the hydrocarbon chain capped the phorbol ester binding groove by interacting with the hydrophobic residues in present in the upper portion (Fig. 14B) making the surface hydrophobic. Because the structure of the εC1B has not been determined yet, a homology modeled structure is generated for the purpose of comparing it with αC1B. Superimposition of the structures revealed remarkable similarity between the overall structure of αC1B and εC1B (Fig. 14C), although several residues in the phorbol ester binding site were different. These residues are most probably responsible for different sensitivity of 4 for PKCα and PKCε. These differences in the residues in the C1B domains are also responsible for the difference in the binding affinity for phorbol ester, phorbol 12, 13-dibutyrate (PDBu) and DAG. For example, αC1B showed lower binding affinity for both phorbol ester and DAG than εC1B ,  implicating different mechanism in PKCα and PKCε activation , . Similarly, in spite of having conserved structure, δC1B binds to DAG/phorbol ester while Vav1 C1 does not .
A) Energy minimized structure of 4. B) Surface diagram of PKCαC1B (blue) docked with 4 (magenta). C) Overlaid structures of αC1B (blue) and εC1B (magenta). Structure of 4 was minimized using Chem3D pro 12.0.2. Molecular docking was done using sybyl 8.0. The protein structures were visualized using UCSF chimera 1.6.1.
That 4 acts on PKCα, which is Ca+2 sensitive, its interactions with the Ca+2 binding C2 domain cannot be completely ruled out. Several studies indicated that fatty acids bound to the phosphatidylserine (PS) – or calcium binding sites of C2 domain. This binding could also affect the binding of C2 domain with the isotype specific RACKs,  responsible for the PKC translocation.
That compound 4 shows reduced cytotoxicity, selectivity towards PKCα and also activated the downstream ERK1/2 either by the Ras →Raf →MEK1/2 →ERK1/2 or the Raf →MEK1/2 →ERK1/2 pathways, this compound can be used as a potential drug for disease states involving PKCα, such as cardiac contractility, atherogenesis, cancer and arterial thrombosis , , . However further studies are required to ascertain if the selectivity of resveratrol and its derivatives is inherent to PKCα or dependent on the dynamic interactions of substrates, modulators and anchoring proteins present in a particular cell/tissue.
In summary, our results demonstrated that resveratrol moiety can be modified suitably as PKC selective modulators. Development of newer synthetic molecules around the resveratrol scaffold and studying their mechanism for isotype selectivity is warranted before any analog can be used as a drug candidate for a particular disease state.
Materials and Methods
Resveratrol, TPA and all other reagents were purchased from Sigma and used without further purification. Progress of chemical reaction was monitored through thin layer chromatography (TLC) on pre-coated glass plates (silica gel 60 F254, 0.25 mm thickness) purchased from EMD chemicals. 1H NMR and 13C NMR spectra were recorded on a QE-300 spectrometer. Unless otherwise specified, all NMR spectra were obtained in deuterated chloroform (CDCl3) and referenced to the residual solvent peak. Chemical shifts are reported in parts per million, and coupling constants in hertz (Hz). Multiplicities are reported as follows: s (singlet), d (doublet), t (triplet), m (multiplet) and br (broadened). Mass spectra were obtained on either a VG 70-S Nier Johnson or JEOL mass spectrometer.
Synthesis of the resveratrol derivatives 2–5
The synthetic procedure of 2–4 is outlined in Figure 15. Compound 1′ was prepared following our previously published methods  with minor modifications. For the synthesis of compounds 2–4, compound 1′ was dissolved in anhydrous pyridine at 0°C and treated with the corresponding acid chloride (oleic acid chloride for 2, linoleic acid chloride for 3 and linolenic acid chloride for 4), which was prepared by the treatment of the corresponding acid (1 equivalent) in anhydrous dichloromethane with thionyl chloride (1.1 equivalent) and catalytic amount of DMF. Acid chloride was distilled under vacuum and used immediately for the next step. The reaction mixture was allowed to stir for 1 h at room temperature and then heated at 60 C for another 2 h. After cooling the mixture to room temperature, excess pyridine was removed in high vacuum. The compound was immediately used for the demethylation step. Demethylation was done by following the methods described earlier . The compounds were purified by column chromatography (hexane: ethyl acetate: methanol, 60∶38∶2) and characterized by NMR spectroscopy and mass spectrometry.
4-((E)-3,5-dihydroxystyryl)phenyl oleate (2): Yield: 77%, 1H NMR (CDCl3, 400 MHz) δ 7.47 (2H, d, J = 8.6 Hz), 7.06 (2H, d, J = 8.2 Hz), 7.00 (1H, d, J = 16.4 Hz), 6.88 (1H, d, J = 16.5 Hz), 6.55 (2H, d, J = 2 Hz), 6.26 (1H, t, J = 2.2 Hz), 5.33 (2H, m), 4.91 (2H, brs), 2.55 (2H, t, J = 7.8 Hz), 2.01 (4H, m), 1.75 (2H, m), 1.42–1.23 (20H, m), 0.86 (3H, t, J = 6.4 Hz); 13C NMR (CDCl3) δ 172.6, 157.0 (2C), 150.01, 139.9, 130.0, 129.8, 128.6 (2C), 128.2, 127.5, 121.9, 121.0 (2C), 106.2 (2C), 102.2, 34.2, 32.0, 29.7, 29.6 (2C), 29.4, 29.1 (2C), 28.9 (2C), 28.8 (2C), 26.8, 26.7, 13.1. ES-MS: 516 [M+Na].
(9Z,12Z)-4-((E)-3,5-dihydroxystyryl)phenyl octadeca-9,12-dienoate (3): Yield: 70%, 1H NMR (CDCl3) δ 7.46 (2H, d, J = 8.5 Hz), 7.06 (2H, d, J = 8.6 Hz), 7.00 (1H, d, J = 16.4 Hz), 6.88 (1H, d, J = 16.5 Hz), 6.51 (2H, d, J = 2.0 Hz), 6.25 (1H, t, J = 2.0 Hz), 5.36 (4H, m), 5.07 (2H, brs), 2.76 (2H, t, J = 5.04 Hz), 2.55 (2H, t, J = 6.0 Hz), 2.04 (4H, m), 1.75 (2H, m), 1.45–1.23 (14H, m), 0.88 (3H, t, J = 5.04 Hz); 13C NMR (CDCl3) δ 172.69, 157.06 (2C), 150.3, 139.9, 134.4, 130.3, 130.1, 128.5, 128.2 (2C), 128.1, 127.6 (2C), 121.9 (2C), 106.2 (2C), 102.4, 34.2, 31.8, 29.6, 29.4, 29.2 (2C), 29.1, 27.2 (2C), 25.7, 24.8, 22.2, 14.1; ES-MS: 514 [M+Na].
(9Z,12Z,15Z)-4-((E)-3,5-dihydroxystyryl)phenyl octadeca-9,12,15-trienoate (4): Yield: 68%, 1H NMR (CDCl3) δ 7.47 (2H, d, J = 8.2 Hz), 7.06 (2H, d, J = 8.7 Hz), 6.98 (1H, d, J = 16.2 Hz), 6.90 (1H, d, J = 16.0 Hz), 6.54 (2H, d, J = 2.0 Hz), 6.26 (1H, t, J = 2.0 Hz), 5.36 (6H, m), 4.95 (2H, brs), 2.80 (4H, t, J = 6.0 Hz), 2.55 (2H, t, J = 7.3 Hz), 2.01 (4H, m), 1.75 (2H, m), 1.42–1.34 (8H, m), 0.96 (3H, t, J = 7.0 Hz); 13C NMR (CDCl3) δ 172.4, 157.04 (2C), 150.37, 140.0, 134.5, 132.0, 130.3, 128.6, 128.3, 128.3, 128.2, 127.8 (2C), 127.5, 121.9 (2C), 106.2 (2C), 102.3, 34.5, 29.6, 29.2 (2C), 29.1, 27.2, 25.7 (2C), 25.6, 21.0, 14.3; ES-MS: 512 [M+Na].
The saturated analog (E)-5-(4-(hexadecyloxy)styryl)benzene-1,3-diol (5) was synthesized and characterized as described earlier .
The UV-Vis absorption (Hitachi U-2910, Hitachi High Technologies America, Inc. Pleasanton, and CA) and fluorescence emission spectra (PTI-Quanta Master, Photon Technology, International, Inc., Birmingham, NJ) of resveratrol (1) and its derivatives (2–5) (1–10 µM) were recorded in different solvents at room temperature. Spectral maxima were determined from the fit of Gaussian function (Igor Pro 4, WaveMatrics, Inc, and Lake Oswego, OR).
CHO-K1 cells were maintained in humidified atmosphere (37°C, 5% CO2) and F12 medium supplemented with 2 mM glutamine, 10% fetal bovine serum (FBS) and 100 unit/ml antibiotics. Before treatment with compounds, cells were starved in without FBS media for 12 h at 60–70% confluency.
The cells were plated overnight in a 96-well plate (Corning, Corning, NY) at a density of 104 cells per well. Cells were either treated with DMSO (1%), resveratrol or derivatives (1–100 µM) for 48 h. Cell viability was determined using Vybrant® MTT cell proliferation assay kit (Molecular Probes/Invitrogen, CA) as per the manufacturer's recommendations.
Membrane fractionation and immunoblot
Compound-treated cells were washed and harvested in PBS. Cell lysis was carried out in lysis buffer (20 mM Tris-HCl, protease inhibitor, pH 7.4) with brief sonication (4 times, 5 second and 10% amplitude). Cell debris was removed by centrifuging the sample at 3500 rpm for 10 minute at 4°C. Protein concentration was measured using the BCA protein assay kit (Pierce, Rockford, IL). Cell lysate (25 µg protein/lane) was subjected to SDS-PAGE and immunoblot to detect protein expression. Cell lysate (200 µg protein/100 µl) was centrifuged at 40,000 rpm for 2 h at 4°C to separate out soluble (cytosolic) and pellet (membrane) fraction. Pellet fraction was incubated in lysis buffer (100 µl) containing 1% Triton X-100 for 1 h in ice, centrifuged at 40,000 rpm for 1 h and the supernatant was collected as the membrane fraction. The cytosolic and membrane fractions (30 µl) were subjected to SDS-PAGE (7%) and transferred to nitrocellulose membrane. Membranes were blocked with TBST (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) buffer containing 10 mg/ml BSA and then washed three times with the TBST buffer. Membranes were probed with primary antibody for overnight at 4°C and HRP-conjugated secondary antibody at room temperature for 1 h. Antibody dilutions were used as follows: anti-rabbit PKCα, 1∶500; anti-rabbit PKCε, 1∶500; anti-rabbit ERK, 1∶1000; anti-rabbit phopho-ERK, 1∶500; anti-rabbit β-actin, 1∶2000 and anti-rabbit HRP-conjugated, 1∶5000 (Cell Signaling, Danvers, MA). The blots were stripped and probed with β-actin and secondary antibody to check for equal loading. Protein bands were visualized using ECL (enhanced chemiluminescence) reagent (Pierce, Rockford, IL) and analyzed by AlphaImager® Gel Documentation system (Alpha Innotec, Santa Clara, CA).
Activation of ERK1/2 was determined by treating the CHO-K1 cells either with 10 µM of the resveratrol derivatives for 24 h or 100 nM TPA for 1 h. ERK1/2 phosphorylation was measured by whole cell lysate immuno-blot analysis using phosphor-ERK1/2 specific antibody.
The chemical structure of 4 was energy minimized using Chem3D pro 12.0.2 (Cambridgesoft) with 1000 iterations. Homology model for PKCεC1B and docking studies were performed using the methods described earlier , . Protein structures were overlaid and visualized using UCSF Chimera 1.6.1.
Conceived and designed the experiments: JD. Performed the experiments: SP AM. Analyzed the data: SP AM JD. Contributed reagents/materials/analysis tools: JD. Wrote the paper: JD SP.
- 1. Pervaiz S (2003) Resveratrol: from grapevines to mammalian biology. FASEB J 17: 1975–1985.
- 2. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB (2002) An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 50: 431–435.
- 3. Wu JM, Hsieh TC (2011) Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 1215: 16–21.
- 4. Petrovski G, Gurusamy N, Das DK (2011) Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 1215: 22–33.
- 5. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jager W (2011) Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci 1215: 89–95.
- 6. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB (2011) Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 1215: 150–160.
- 7. Shukla Y, Singh R (2011) Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 1215: 1–8.
- 8. Richard T, Pawlus AD, Iglesias ML, Pedrot E, Waffo-Teguo P, et al. (2011) Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci 1215: 103–108.
- 9. Gusman J, Malonne H, Atassi G (2001) A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111–1117.
- 10. Fremont L (2000) Biological effects of resveratrol. Life Sci 66: 663–673.
- 11. Belguendouz L, Fremont L, Linard A (1997) Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53: 1347–1355.
- 12. Gehm BD, McAndrews JM, Chien PY, Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 94: 14138–14143.
- 13. MacCarrone M, Lorenzon T, Guerrieri P, Agro AF (1999) Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem 265: 27–34.
- 14. Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM (1996) Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 246: 163–182.
- 15. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235: 207–219.
- 16. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218–220.
- 17. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, et al. (2000) Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158: 85–91.
- 18. Surh YJ, Hurh YJ, Kang JY, Lee E, Kong G, et al. (1999) Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett 140: 1–10.
- 19. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, et al. (2002) Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8: 893–903.
- 20. Kuo PL, Chiang LC, Lin CC (2002) Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci 72: 23–34.
- 21. Mgbonyebi OP, Russo J, Russo IH (1998) Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865–869.
- 22. Ratan HL, Steward WP, Gescher AJ, Mellon JK (2002) Resveratrol–a prostate cancer chemopreventive agent? Urol Oncol 7: 223–227.
- 23. Hsieh TC, Wu JM (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109–115.
- 24. Morris GZ, Williams RL, Elliott MS, Beebe SJ (2002) Resveratrol induces apoptosis in LNCaP cells and requires hydroxyl groups to decrease viability in LNCaP and DU 145 cells. Prostate 52: 319–329.
- 25. Schwedhelm E, Maas R, Troost R, Boger RH (2003) Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet 42: 437–459.
- 26. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, et al. (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215: 161–169.
- 27. Pervaiz S, Holme AL (2009) Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 11: 2851–2897.
- 28. Pirola L, Frojdo S (2008) Resveratrol: one molecule, many targets. IUBMB Life 60: 323–332.
- 29. Nakashima S (2002) Protein kinase C alpha (PKC alpha): regulation and biological function. J Biochem 132: 669–675.
- 30. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, et al. (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10: 248–254.
- 31. Konopatskaya O, Poole AW (2010) Protein kinase Calpha: disease regulator and therapeutic target. Trends Pharmacol Sci 31: 8–14.
- 32. Battaini F, Mochly-Rosen D (2007) Happy birthday protein kinase C: past, present and future of a superfamily. Pharmacol Res 55: 461–466.
- 33. Koivunen J, Aaltonen V, Peltonen J (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett 235: 1–10.
- 34. Griner EM, Kazanietz MG (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7: 281–294.
- 35. Das Evcimen N, King GL (2007) The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55: 498–510.
- 36. Bright R, Mochly-Rosen D (2005) The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke 36: 2781–2790.
- 37. Chou WH, Messing RO (2005) Protein kinase C isozymes in stroke. Trends Cardiovasc Med 15: 47–51.
- 38. Sabri A, Steinberg SF (2003) Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem 251: 97–101.
- 39. Alkon DL, Sun MK, Nelson TJ (2007) PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol Sci 28: 51–60.
- 40. Hofmann J (2004) Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4: 125–146.
- 41. Newton AC (2001) Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 101: 2353–2364.
- 42. Nishizuka Y (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258: 607–614.
- 43. Das J, Addona GH, Sandberg WS, Husain SS, Stehle T, et al. (2004) Identification of a general anesthetic binding site in the diacylglycerol-binding domain of protein kinase Cdelta. J Biol Chem 279: 37964–37972.
- 44. Das J, Zhou X, Miller KW (2006) Identification of an alcohol binding site in the first cysteine-rich domain of protein kinase Cdelta. Protein Sci 15: 2107–2119.
- 45. Das J, Pany S, Rahman GM, Slater SJ (2009) PKC epsilon has an alcohol-binding site in its second cysteine-rich regulatory domain. Biochem J 421: 405–413.
- 46. Atten MJ, Godoy-Romero E, Attar BM, Milson T, Zopel M, et al. (2005) Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest New Drugs 23: 111–119.
- 47. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, et al. (1998) Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273: 21875–21882.
- 48. Stewart JR, O'Brian CA (2004) Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 22: 107–117.
- 49. Stewart JR, Ward NE, Ioannides CG, O'Brian CA (1999) Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38: 13244–13251.
- 50. Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ (2003) Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta 1637: 59–69.
- 51. Ferrero ME, Bertelli AE, Fulgenzi A, Pellegatta F, Corsi MM, et al. (1998) Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 68: 1208–1214.
- 52. Chen CK, Pace-Asciak CR (1996) Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 27: 363–366.
- 53. Kimura Y, Okuda H, Arichi S (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 834: 275–278.
- 54. Das J, Pany S, Majhi A (2011) Chemical modifications of resveratrol for improved protein kinase C alpha activity. Bioorg Med Chem 19: 5321–5333.
- 55. Babich H, Reisbaum AG, Zuckerbraun HL (2000) In vitro response of human gingival epithelial S-G cells to resveratrol. Toxicol Lett 114: 143–153.
- 56. Shirai Y, Kashiwagi K, Yagi K, Sakai N, Saito N (1998) Distinct effects of fatty acids on translocation of gamma- and epsilon-subspecies of protein kinase C. J Cell Biol. 143: 511–521.
- 57. Yang YM, Wang XX, Chen JZ, Wang SJ, Hu H, et al. (2008) Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity. Am J Chin Med 36: 603–613.
- 58. Endo Y, Yokoyama A (2000) Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams. Bioorg Med Chem Lett 10: 63–66.
- 59. Wooten MW, Wrenn RW (1988) Linoleic acid is a potent activator of protein kinase C type III-alpha isoform in pancreatic acinar cells; its role in amylase secretion. Biochem Biophys Res Commun 153: 67–73.
- 60. Shinomura T, Asaoka Y, Oka M, Yoshida K, Nishizuka Y (1991) Synergistic action of diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible implications. Proc Natl Acad Sci U S A 88: 5149–5153.
- 61. Murakami K, Chan SY, Routtenberg A (1986) Protein kinase C activation by cis-fatty acid in the absence of Ca2+ and phospholipids. J Biol Chem 261: 15424–15429.
- 62. Pi Y, Walker JW (2000) Diacylglycerol and fatty acids synergistically increase cardiomyocyte contraction via activation of PKC. Am J Physiol Heart Circ Physiol 279: H26–34.
- 63. Yaguchi T, Yamamoto S, Nagata T, Kanno T, Tanaka A, et al. (2005) Effects of cis-unsaturated free fatty acids on PKC-epsilon activation and nicotinic ACh receptor responses. Brain Res Mol Brain Res 133: 320–324.
- 64. Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB (2001) Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry 6: 246–248.
- 65. Prades J, Funari SS, Escriba PV, Barcelo F (2003) Effects of unsaturated fatty acids and triacylglycerols on phosphatidylethanolamine membrane structure. J Lipid Res 44: 1720–1727.
- 66. Rawicz W, Olbrich KC, McIntosh T, Needham D, Evans E (2000) Effect of chain length and unsaturation on elasticity of lipid bilayers. Biophys J 79: 328–339.
- 67. Yamatsugu K, Motoki R, Kanai M, Shibasaki M (2006) Identification of potent, selective protein kinase C inhibitors based on a phorbol skeleton. Chem Asian J 1: 314–321.
- 68. Wada R, Suto Y, Kanai M, Shibasaki M (2002) Dramatic switching of protein kinase C agonist/antagonist activity by modifying the 12-ester side chain of phorbol esters. J Am Chem Soc 124: 10658–10659.
- 69. Sodeoka M, Arai MA, Adachi K, Uotsu K, Shibasaki M (1998) Rational Design, Synthesis, and Evaluation of a New Type of PKC Inhibitor. J Am Chem Soc 120: 457–458.
- 70. Irie K, Oie K, Nakahara A, Yanai Y, Ohigashi H, et al. (1998) Molecular basis for Protein Kinase C isozyme-selective binding: the systhesis, folding, and phorbol ester binding of the cysteine-rich domains of all Protein Kinase C isozymes. J Am Chem Soc 120: 9159–9167.
- 71. Ananthanarayanan B, Stahelin RV, Digman MA, Cho W (2003) Activation mechanisms of conventional protein kinase C isoforms are determined by the ligand affinity and conformational flexibility of their C1 domains. J Biol Chem 278: 46886–46894.
- 72. Stahelin RV, Digman MA, Medkova M, Ananthanarayanan B, Melowic HR, et al. (2005) Diacylglycerol-induced membrane targeting and activation of protein kinase Cepsilon: mechanistic differences between protein kinases Cdelta and Cepsilon. J Biol Chem 280: 19784–19793.
- 73. Geczy T, Peach ML, El Kazzouli S, Sigano DM, Kang JH, et al. (2012) Molecular basis for failure of “atypical” C1 domain of Vav1 to bind diacylglycerol/phorbol ester. J Biol Chem 287: 13137–13158.
- 74. Aires V, Hichami A, Filomenko R, Ple A, Rebe C, et al. (2007) Docosahexaenoic acid induces increases in [Ca2+]i via inositol 1,4,5-triphosphate production and activates protein kinase C gamma and -delta via phosphatidylserine binding site: implication in apoptosis in U937 cells. Mol Pharmacol 72: 1545–1556.
- 75. Kanno T, Yamamoto H, Yaguchi T, Hi R, Mukasa T, et al. (2006) The linoleic acid derivative DCP-LA selectively activates PKC-epsilon, possibly binding to the phosphatidylserine binding site. J Lipid Res 47: 1146–1156.
- 76. Nelson TJ, Cui C, Luo Y, Alkon DL (2009) Reduction of beta-amyloid levels by novel protein kinase C(epsilon) activators. J Biol Chem 284: 34514–34521.
- 77. Banci L, Cavallaro G, Kheifets V, Mochly-Rosen D (2002) Molecular dynamics characterization of the C2 domain of protein kinase Cbeta. J Biol Chem 277: 12988–12997.
- 78. Liu Q, Molkentin JD (2011) Protein kinase Calpha as a heart failure therapeutic target. J Mol Cell Cardiol 51: 474–478.
- 79. Teicher BA (2006) Protein kinase C as a therapeutic target. Clin Cancer Res 12: 5336–5345.
- 80. Majhi A, Rahman GM, Panchal S, Das J (2010) Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C. Bioorg Med Chem. 18: 1591–1598.